Brief: Instil Bio Reports Third Quarter 2022 Financial Results

Instil Bio

14/11/2022 21:47

Nov 14 (Reuters) - Instil Bio Inc  TIL.O :
    * INSTIL BIO REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
AND
PROVIDES CORPORATE UPDATE
    * CONFIRMS CASH RUNWAY INTO 2025 WITH ANTICIPATED
SALE-LEASEBACK
TRANSACTION OF ITS TARZANA MANUFACTURING FACILITY
    * QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.43
    * FIRST PATIENT WITH NON-SMALL CELL LUNG CANCER DOSED WITH
ITIL-306 WITH PLANS TO SHARE CLINICAL DATA IN 2023
    * Q3 EARNINGS PER SHARE VIEW $-0.44 -- REFINITIV IBES DATA
    * REPRIORITIZATION OF RESOURCES WITH ENROLLMENT DEFERRED IN
DELTA-2 TRIAL OF ITIL-168
    * MANUFACTURING UPDATE ON VOLUNTARY PAUSE OF DELTA-1 TRIAL
OF
ITIL-168 IN ADVANCED MELANOMA EXPECTED IN Q1'23

Source text for Eikon:  ID:nGNXbdsz0z 
Further company coverage:  TIL.O 
 ((Reuters.Briefs@thomsonreuters.com;))